Researchers in Japan Study Inhalable Gene Therapy for Mesothelioma

This study suggests that inhalable gene drugs are effective treatments for NSCLC and MPM,” the authors wrote. “These findings suggest that cancer gene therapy using inhalable drugs may constitute a novel therapeutic regimen and improve patients’ qualify of life owing to the low invasiveness of the mode of administration.” Effective, Noninvasive Treatment Is Rare Aggressive treatment for mesothelioma is hard on patients, and may lead to a significantly decreased quality of life. Major mesothelioma surgery can be physically overwhelming and its side effects long-lasting. Standard-of-care chemotherapy, the most common treatment, often comes with tough side effects and limited effectiveness. In laboratory testing using both lung cancer and mesothelioma cell lines, there was a clear decrease in tumor cell proliferation with the laboratory engineered drugs, according to the study. The growth inhibition rate was almost 50% using SFD-p16, compared to just 9.3% for the placebo group. SFD-p53 produced a 52.1% growth inhibition rate. In vivo testing using mouse models injected with the tumor cell lines produced similar results with both lung cancer and mesothelioma, particularly involving the drug SFD-p16. Using luminescence imaging, researchers documented tumor suppression within 24 hours after administration of the drug. Tumors were removed in a week and showed significant change in volume. The research team at the Institute for Advanced Medical Sciences at H...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Clinical Trials/Research/Emerging Treatments Pleural Source Type: news